Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS

The impact of TP53 mutations (TP53MT) and their allelic status, as defined by multiple classifications, on response and survival with hypomethylating agents (HMA) in patients with higher risk myelodysplastic syndromes (HR-MDS), particularly in the setting of undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT), remains incompletely understood. We analyzed 1,485 HR-MDS patients from the International Consortium for MDS (icMDS) VALIDATE database, including 392 patients with TP53MT who were treated with HMA. Biallelic TP53MT was defined using WHO 2022 and ICC 2022 methods. Monoallelic TP53MT was identified in only 4% of the cases per ICC 2022, reflecting the poor risk nature of our cohort. Patients with TP53MT had inferior overall survival compared to those with wild-type TP53 (OS: 11.5 vs. 23.9 months; p < 0.001). Using either the ICC 2022 or WHO 2022 definitions, the allelic status did not impact survival. Among HR-MDS patients with less than 10% blasts, a TP53 VAF < 10% identified a subgroup with better OS than biallelic TP53MT. However, no difference in OS was observed among patients with biallelic, monoallelic or VAF < 10% TP53MT when stratified according to the blast percentage (10–19% vs. 0–9% blasts). In patients with TP53MT, achieving a complete or composite complete remission (CR/cCR) per the IWG 2023 criteria was associated with improved OS among patients who did not undergo subsequent allo-HCT (HR: 0.5; 95% CI: 0.3–0.7), but not in those who underwent allo-HCT. However, allo-HCT was associated with a survival benefit regardless of allelic status or response to HMA. Unsupervised clustering identified a low-VAF molecular subgroup with favorable outcomes (HR: 0.6; 95% CI: 0.4–0.8), though a VAF ≥ 19% predicted worse OS even after transplant. These findings provide important insights into the critical role of TP53 mutations in patients with HR-MDS across different clinical contexts.

Authors

Institutions

Publication Details

Journal
Blood Cancer Journal
Published
2026-11-14
DOI
https://doi.org/10.1038/s41408-026-01584-x
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS

Vasiliki Pappa, Aref Al‐Kali, Andrew Mark Brunner, Rami S. Komrokji et al.
1 links
Blood Cancer Journal
Acute Myeloid Leukemia Research
article

Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS

Vasiliki Pappa, Aref Al‐Kali, Andrew Mark Brunner, Rami S. Komrokji, Aram Bidikian, Yasmin Abaza, Gail J. Roboz, Ιoannis Kotsianidis, Anoop Kumar Enjeti, Hetty E. Carraway, David Valcárcel, Claudia Haferlach, David Andrew Sallman, Angela Consagra, Amy Elizabeth Dezern, Eunice S. Wang, Tariq Zuheir Kewan, Joshua F. Zeidner, Somedeb Ball, Seishi Ogawa, Maria L. Amaya, Torsten Haferlach, Jessica M. Stempel, Zhuoer Xie, Ondřej Bláha, Michael Robert Savona, Lisa Pleyer, Hayley Hawkins, Mikkael Aaron Sekeres, Devendra Hiwase, Namrata S. Chandhok, Elizabeth A. Griffiths, Benjamin Rolles, María Díez‐Campelo, Khalid Halahleh, Yasuhito Nannya, Eytan M. Stein, Amer Methqal Zeidan, Talha Badar, Jan Philipp Bewersdorf, Jaroslaw Pawel Maciejewski, Luca Lanino, Matteo Giovanni Della Porta, Yazan F. Madanat, Rory Michael Shallis, Valeria Santini, Abi Harris, Najla H. Al Ali, Christine McMahon, Ted M. Getz, Maximilian Stahl, Geoffrey L Uy, Pinkal Desai, Samuel Urrutia, Kamal Al-Rabi, Justin Grenet, Constantine Logothetis
article en

Abstract

The impact of TP53 mutations (TP53MT) and their allelic status, as defined by multiple classifications, on response and survival with hypomethylating agents (HMA) in patients with higher risk myelodysplastic syndromes (HR-MDS), particularly in the setting of undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT), remains incompletely understood. We analyzed 1,485 HR-MDS patients from the International Consortium for MDS (icMDS) VALIDATE database, including 392 patients with TP53MT who were treated with HMA. Biallelic TP53MT was defined using WHO 2022 and ICC 2022 methods. Monoallelic TP53MT was identified in only 4% of the cases per ICC 2022, reflecting the poor risk nature of our cohort. Patients with TP53MT had inferior overall survival compared to those with wild-type TP53 (OS: 11.5 vs. 23.9 months; p < 0.001). Using either the ICC 2022 or WHO 2022 definitions, the allelic status did not impact survival. Among HR-MDS patients with less than 10% blasts, a TP53 VAF < 10% identified a subgroup with better OS than biallelic TP53MT. However, no difference in OS was observed among patients with biallelic, monoallelic or VAF < 10% TP53MT when stratified according to the blast percentage (10–19% vs. 0–9% blasts). In patients with TP53MT, achieving a complete or composite complete remission (CR/cCR) per the IWG 2023 criteria was associated with improved OS among patients who did not undergo subsequent allo-HCT (HR: 0.5; 95% CI: 0.3–0.7), but not in those who underwent allo-HCT. However, allo-HCT was associated with a survival benefit regardless of allelic status or response to HMA. Unsupervised clustering identified a low-VAF molecular subgroup with favorable outcomes (HR: 0.6; 95% CI: 0.4–0.8), though a VAF ≥ 19% predicted worse OS even after transplant. These findings provide important insights into the critical role of TP53 mutations in patients with HR-MDS across different clinical contexts.

Blood Cancer Journal
Northwestern University (US), University of North Carolina at Chapel Hill (US), Universitat Autònoma de Barcelona (ES), Brigham and Women's Hospital (US), Roswell Park Comprehensive Cancer Center (US), Cleveland Clinic (US), Royal Adelaide Hospital (AU), Mayo Clinic (US), Memorial Sloan Kettering Cancer Center (US), Humanitas University (IT), Harvard University (US), Johns Hopkins University (US), University of Miami (US), Democritus University of Thrace (GR), Universidad de Salamanca (ES), National and Kapodistrian University of Athens (GR), Washington University in St. Louis (US), Kyoto University (JP), Paracelsus Medical University (AT), King Hussein Cancer Center (JO), Moffitt Cancer Center (US), Yale University (US), Massachusetts General Hospital (US), Munich Leukemia Laboratory (Germany) (DE), Azienda Ospedaliero-Universitaria Careggi (IT), Dana-Farber Cancer Institute (US), Arbeitsgemeinschaft medikamentöse Tumortherapie (AT), South Australian Health and Medical Research Institute (AU), University General Hospital Attikon (GR), Mayo Clinic in Florida (US), Calvary Mater Newcastle Hospital (AU), Australasian Leukaemia and Lymphoma Group (AU), Sylvester Comprehensive Cancer Center (US), IRCCS Humanitas Research Hospital (IT), Sidney Kimmel Comprehensive Cancer Center (US), Weill Cornell Medicine (US), Vall d'Hebron Institute of Oncology (ES), Vanderbilt-Ingram Cancer Center (US), UNC Lineberger Comprehensive Cancer Center (US), Harold C. Simmons Comprehensive Cancer Center (US), Adelaide University (AU), Institute for the Advanced Study of Human Biology, Kyoto University (JP), University of Florence (IT), The University of Adelaide (AU), The University of Texas Southwestern Medical Center (US), Vanderbilt University Medical Center (US)
Dana-Farber Cancer Institute, Associazione Italiana per la Ricerca sul Cancro, Deutsche Krebshilfe
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon